Fujian Cosunter Pharmaceutical Co Ltd banner
F

Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436

Watchlist Manager
Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436
Watchlist
Price: 123.05 CNY -3.83%
Market Cap: ¥19.6B

Relative Value

The Relative Value of one Fujian Cosunter Pharmaceutical Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 123.05 CNY, Fujian Cosunter Pharmaceutical Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Fujian Cosunter Pharmaceutical Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Fujian Cosunter Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436
19.6B CNY 45.5 -99.4 -123.9 -123.9
US
Eli Lilly and Co
NYSE:LLY
982.7B USD 15.1 47.6 32.1 34.1
US
Johnson & Johnson
NYSE:JNJ
586.1B USD 6.2 21.9 15.2 18.7
CH
Roche Holding AG
SIX:ROG
292.8B CHF 4.8 31.1 13.1 15.3
UK
AstraZeneca PLC
LSE:AZN
240.1B GBP 5.6 32.1 17.7 24.9
CH
Novartis AG
SIX:NOVN
247.3B CHF 5.6 22.7 14 17.9
US
Merck & Co Inc
NYSE:MRK
302.6B USD 4.7 16.6 10.3 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.4 9.8 11.5
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
156.1B USD 2.5 20.1 7.5 10
UK
GlaxoSmithKline PLC
LSE:GSK
91B GBP 2.8 16 8 11.4
P/E Multiple
Earnings Growth PEG
CN
F
Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436
Average P/E: 24.6
Negative Multiple: -99.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.6
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.9
7%
3.1
CH
Roche Holding AG
SIX:ROG
31.1
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
32.1
26%
1.2
CH
Novartis AG
SIX:NOVN
22.7
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.6
14%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
7%
1.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
20.1
26%
0.8
UK
GlaxoSmithKline PLC
LSE:GSK
16
18%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
F
Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436
Average EV/EBITDA: 46.1
Negative Multiple: -123.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.1
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
13.1
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
17.7
11%
1.6
CH
Novartis AG
SIX:NOVN
14
9%
1.6
US
Merck & Co Inc
NYSE:MRK
10.3
7%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
7%
1.4
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
8
2%
4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
F
Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436
Average EV/EBIT: 99.1
Negative Multiple: -123.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.1
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.7
6%
3.1
CH
Roche Holding AG
SIX:ROG
15.3
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
24.9
24%
1
CH
Novartis AG
SIX:NOVN
17.9
12%
1.5
US
Merck & Co Inc
NYSE:MRK
12.1
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
8%
1.4
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10
-1%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
11.4
12%
0.9